# **EpiChron Cohort**

First published: 01/02/2024

Last updated: 17/10/2024

Data source

Human

Hospital discharge records

Other

**Pharmacy dispensing records** 

# Administrative details

### Administrative details

#### **PURI**

https://redirect.ema.europa.eu/resource/22494

#### **Data source ID**

22494

#### **Data holder**

EpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS)

#### **Data source type**

Hospital discharge records

Other

Pharmacy dispensing records

#### Data source type, other

Electronic health records

#### Main financial support

Funding by own institution

#### **Care setting**

Hospital inpatient care

Primary care - GP, community pharmacist level

Primary care - specialist level (e.g. paediatricians)

Secondary care – specialist level (ambulatory)

#### **Data source qualification**

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

#### **Data source website**

https://epichron.com/

## Contact details

### Beatriz Poblador Plou



bpoblador.iacs@aragon.es

# Data source regions and languages

#### **Data source countries**

Spain

#### **Data source languages**

Spanish

## Data source establishment

#### **Data source established**

15/06/2011

#### Data source time span

First collection: 15/06/2012

The date when data started to be collected or extracted.

### **Publications**

### Data source publications

Jordi Castellsague, Susana Perez-Gutthann, Brian Calingaert, Christine Bui, Cristina Varas-Lorenzo, Alejandro Arana, Alexandra Prados-Torres, Beatriz Poblador-Plou, Francisca Gonzalez-Rubio, Maria Giner-Soriano, Albert Roso-Llorach, Marie Linder, Anna Citarella, Oliver Scholle, Edeltraut Garbe. Characterization of new users of cilostazol in the United Kingdom, Spain, Sweden, and Germany. Pharmacoepidemiology & Drug Safety. 2017 Jun26(6):615-624. Epub 2017 Jan 30.

Calderón A, Diaz E, Poblador B, Gimeno LA, Abad JM, Prados A. Non-adherence to antihypertensive medication: the role of mental and physical comorbidity. International Journal of Cardiology. 2016 Jan 11 207:310-316.

Malo S, Poblador-Pou B, Prados-Torres A, Lallana MJ, Laguna-Berna C and Rabanaque MJ. Poor congruence with guidelines in the use of antibiotics for acute bronchitis: a descriptive study based on electronic health records. Fam Pract. 2016 Oct33(5):471-5. Epub 2016 May 24

Prados-Torres A, Poblador-Plou B, Gimeno-Miguel A, Calderón-Larrañaga A, Poncel-Falcó A, Gimeno-Feliú LA, González-Rubio F, Laguna-Berna C, Marta-Moreno J, Clerencia-Sierra M, Aza-Pascual-Salcedo M, Bandrés-Liso AC, Coscollar-Santaliestra C, Pico-Soler V, Abad-Díez JM. Cohort Profile: The Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study. Int J Epidemiol. 2018 Jan 16. doi: 10.1093/ije/dyx259. [Epub ahead of print] PubMed PMID: 29346556.

Diaz E, Poblador B, Gimeno LA, Calderón A, Kumar BN, Prados A. Multimorbidity and Its Patterns according to Immigrant Origin. A Nationwide Register-Based Study in Norway. PLoS One. 2015 Dec 18 10(12):e0145233.

### **Studies**

# List of studies that have been conducted using the data source

Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine

Post-Authorisation Active Surveillance Study of Myocarditis and Pericarditis

Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease

2019 (COVID-19) Vaccine

Strengthening Use of Real-World Data in Medicines Development: Metadata for Data Discoverability and Study Replicability (MINERVA)

Post-Authorisation Safety Study of Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4-5 in Europe

SAFETY-VAC: Network of Data Sources for Vaccine Safety Evaluation

SAFETY-VAC: Background incidence estimation of flares of pre-existing chronic diseases using pan-European electronic healthcare data sources. (SAFETY VAC)

SAFETY-VAC: Phenotype proposal and rates of immunocompromised populations in real-world data sources.

VAC4EU Postauthorisation Safety Study of BIMERVAX® Vaccine in Europe

VAC4EU Postauthorisation Effectiveness Study of BIMERVAX® Vaccine in Europe

A Post-Authorisation Safety Study (PASS) of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK

A post-authorisation safety study of ABRYSVO in immunocompromised, or renally or hepatically impaired adults aged 60 years and older in a real world setting in Europe and UK

### Data elements collected

The data source contains the following information

Disease information

Does the data source collect informatio registry or other similar initiatives.	n with a focus on a specific disease? This might be a patient
No	
Rare diseases	
Are rare diseases captured? In the Euro	pean Union a rare disease is one that affects no more than 5
people in 10,000.	
No	
Pregnancy and/or neonates	
Does the data source collect informatio	n on pregnant women and/or neonatal subpopulation (under
28 days of age)?	
Yes	

## Hospital admission and/or discharge

Yes

#### **ICU** admission

Is information on intensive care unit admission available?

Yes

#### **Cause of death**

Not Captured

### **Prescriptions of medicines**

Captured

### **Prescriptions vocabulary**

**ATC** 

# **Dispensing of medicines** Captured Dispensing vocabulary **ATC** Advanced therapy medicinal products (ATMP) Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)]. No **Contraception** Is information on the use of any type of contraception (oral, injectable, devices etc.) available? No Indication for use Does the data source capture information on the therapeutic indication for the use of medicinal products? Not Captured

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

**Medical devices** 

**Administration of vaccines** 

No

Yes

**Procedures** 

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

#### Captured

### **Procedures vocabulary**

ICD-10-CM

#### **Healthcare** provider

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available? The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

No

#### **Clinical measurements**

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

#### **Genetic data**

Are data related to genotyping, genome sequencing available?

Not Captured

#### Biomarker data

Does the data source capture biomarker information? The term "biomarker" refers to a broad subcategory of medical signs ( objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Not Captured

#### **Patient-reported outcomes**

Is information on patient-reported outcomes (e.g., quality of life) available?

No

#### **Patient-generated data**

Is patient-generated information (e.g., from wearable devices) available?

No

#### Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

No

#### **Unique identifier for persons**

Are patients uniquely identified in the data source?

No

#### **Diagnostic codes**

Captured

#### Diagnosis / medical event vocabulary

ICD-10-CM

ICD-9-CM

**ICPC** 

#### **Medicinal product information**

Not Captured

#### **Quality of life measurements**

Not Captured

#### **Lifestyle factors**

Captured

#### Lifestyle factors

Alcohol use

Tobacco use

#### **Sociodemographic information**

Captured

### Sociodemographic information collected

Age

Country of origin

Gender

Health area

Living in rural area

Pharmaceutical copayment

# Quantitative descriptors

# Population Qualitative Data

#### Population age groups

Paediatric Population (< 18 years)

Preterm newborn infants (0 - 27 days)

Term newborn infants (0 - 27 days)

Infants and toddlers (28 days - 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

# Estimated percentage of the population covered by the data source in the catchment area

98%. Includes population covered by Regional health care system.

Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)

Regional sub-set - Northeast Spanish region of Aragón (1.3 M inhabitants)

# Family linkage

Family linkage available in the data source permanently or can be created on an ad hoc basis

Permanently

Family linkage available between the following persons

Mother-child

# **Population**

#### **Population size**

1851418

#### **Active population size**

1298794

# Data flows and management

## Access and validation

#### **Biospecimen access**

Are biospecimens available in the data source (e.g., tissue samples)?

No

#### Access to subject details

Can individual patients/practitioners/practices included in the data source be contacted?

No

# Event triggering registration

#### Event triggering registration of a person in the data source

Birth

**Immigration** 

#### Event triggering de-registration of a person in the data source

Death

**Emigration** 

# Data source linkage

#### Linkage

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

Nο

# Data management specifications that apply for the data source

#### **Data source refresh**

Yearly

#### Informed consent for use of data for research

Other

#### Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

Yes

#### **Data source preservation**

Are records preserved in the data source indefinitely?

No

#### **Approval for publication**

Is an approval needed for publishing the results of a study using the data source?

No

#### Informed consent, other

There is a committee to evaluate requests for data access

# Common Data Model (CDM) mapping

Yes	
CDM Mappings	
CDM name	
ConcepTION CDM	
CDM website	
https://www.imi-conception.eu/	
CDM release frequency	
6 months	
Data source ETL CDM version	
2.2	
Data source ETL status	
Completed	
CDM name	
OMOP	
CDM website	
https://www.ohdsi.org/Data-standardization/	

**CDM** mapping